Your browser doesn't support javascript.
loading
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML.
Ritchie, Ellen K; Cella, David; Fabbiano, Francesco; Pigneux, Arnaud; Kanda, Yoshinobu; Ivanescu, Cristina; Pandya, Bhavik J; Shah, Manasee V.
Afiliação
  • Ritchie EK; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.
  • Cella D; Department of Medical Social Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
  • Fabbiano F; Department of Hematology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
  • Pigneux A; Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
  • Kanda Y; Division of Hematology, Jichi Medical University, Tochigi, Japan.
  • Ivanescu C; Patient Centered Solutions, IQVIA, Amsterdam, Netherlands.
  • Pandya BJ; Medical Affairs, Astellas Pharma, Inc., Northbrook, IL, USA.
  • Shah MV; Medical Affairs, Astellas Pharma, Inc., Northbrook, IL, USA.
Leuk Lymphoma ; 64(5): 938-950, 2023 05.
Article em En | MEDLINE | ID: mdl-37019445
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article